|
Coming Soon to Metastatic Trial Search (specific for breast cancer)
These breast cancer clinical trials have recently been added to ClinicalTrials.gov, the
website that lists all clinical trials in the U.S. You will be able to match to them within the
next two weeks and see information in our patient-friendly format on all Metastatic Trial
Search partner sites as well as on MBC Connect.
Additional Brain Mets Trials
All brain mets trials currently recruiting in the U.S. are included on Metastatic Trial Search.
Click links below to see brain mets trials outside of the U.S., as well as brain mets trials that
are not currently recruiting.
Solid Tumor Cancer Trials (not specific for breast cancer)
This list of Phase I and Phase I/II trials is provided and updated by metastatic breast cancer patient and advocate, Christine Hodgdon, of the Storm Riders Network.
Tell me more about these trials
Why do I see this list?
The MTS matching service does not include some small Phase I trials that are enrolling patients with any type of solid tumor. We also do not list Phase I/II trials in which Phase II is not enrolling breast cancer patients. But we think it is important to make sure you can find these trials if you are interested in them.What are Phase I and Phase I/II trials?
Phase I trials evaluate the safety, side effects, and best dose of a new treatment in humans for the first time. They are not primarily focused on evaluating the benefit of treatment and enroll a very small number of people at very few locations. Phase I and Phase II trials are sometimes designed as a combined Phase I/II trial with all cancer types in Phase I but only certain cancer types in Phase II.Does MTS include any Phase I or Phase I/II trials?
Yes. We include all Phase I trials that are specifically enrolling breast cancer patients. We also include any Phase I/II trial where Phase II is specifically enrolling breast cancer patients, even if Phase I is for all solid tumors.How often will this list be updated?
This list will be updated monthly.Immunotherapy Trials (363)
- Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors (NCT04572451)
- Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs) (NCT04375228)
- First in Human Study of M1069 in Advanced Solid Tumors (NCT05198349)
- ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors (NCT05277402)
- A Phase 1/2 Study in Patients With Advanced Cancers (NCT05320588)
- HCW9218 in Select Advanced Solid Tumors (NCT05322408)
- Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors (NCT05352750)
- A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients (NCT04501276)
- Intratumoral CAN1012 in Subjects With Solid Tumors (NCT04987112)
- XTX202 in Patients With Advanced Solid Tumors (NCT05052268)
- A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001) (NCT05067283)
- Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT05098132)
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors (NCT05108623)
- A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors (NCT05129280)
- A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors) (NCT05155332)
- A Study of TAK-103 in Adult With Solid Tumors (NCT05164666)
- PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors (NCT05233436)
- Dose Escalation Study of IO-108 and IO-108+Pembrolizumab in Solid Tumors (NCT05054348)
- First Line Platinum/Etoposide With or Without Atezolizumab for the Treatment of Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Cancer (NCT05058651)
- Study of PF-07263689 in Participants With Selected Advanced Solid Tumors (NCT05061537)
- A Study of ZL-1211 in Patients With Advanced Solid Tumor (NCT05065710)
- Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (NCT05099549)
- A Cancer Vaccine (Labvax 3(22-23 and GM-CSF for the Treatment of Advanced Stage Adenocarcinoma (NCT05101356)
- A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma (NCT05115292)
- A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (NCT05117476)
- A Study of NDI 1150-101 in Patients With Solid Tumors (NCT05128487)
- IPG7236 in Patients With Advanced Solid Tumors (NCT05142592)
- S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers (NCT05162755)
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression (NCT05163041)
- Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (NCT05176483)
- Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors (NCT05204862)
- A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors (NCT02663518)
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults (NCT03445858)
- Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors (NCT04121442)
- Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (NCT04165330)
- ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (NCT04205227)
- Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas (NCT04701307)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (NCT04840589)
- Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (NCT04900519)
- A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) (NCT04958239)
- Study of INCA 0186 in Subjects With Advanced Solid Tumors (NCT04989387)
- First in Human, Dose Escalation Study of AN4005 (NCT04999384)
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab (NCT05005403)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18) (NCT05017012)
- NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies (NCT05023486)
- A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors (NCT05025085)
- Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors (NCT05037149)
- A Study of Pembrolizumab (MK-3475 in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051 (NCT02332668)
- Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies (NCT04648826)
- Study to Evaluate the Safety and Tolerability of GS-1811 as Monotherapy and in Combination With Pembrolizumab in Adults With Advanced Solid Tumors (NCT05007782)
- Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors (NCT05013554)
- IACS-6274 With or Without Pembrolizumab for the Treatment of Advanced Solid Tumors (NCT05039801)
- Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer (NCT02862275)
- Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers (NCT04171219)
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (NCT05060432)
- A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults (NCT04999202)
- Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study (NCT04887870)
- XTX101 in Patients With Advanced Solid Tumors (NCT04896697)
- Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors (NCT04975958)
- Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Percutaneously Accessible Advanced Solid Tumors (NCT04796194)
- Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors (NCT04727554)
- Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor (NCT04800627)
- Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (NCT04902040)
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers (NCT02908906)
- NL-201 in Patients With Relapsed or Refractory Cancer (NCT04659629)
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT04898543)
- A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO in Subjects With Advanced Solid Tumors (NCT04690699)
- Phase I Study of CPI-300 in Patients With Advanced Tumors (NCT04808453)
- A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors (NCT04843709)
- A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors (NCT04903873)
- Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (NCT05018273)
- Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04958434)
- Phase II Trial of Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors (NCT04056910)
- Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer (NCT04708470)
- Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04840394)
- ALPN-202 With PD-1 Inhibition in Advanced Malignancies (NCT04920383)
- PK Study to Assess Drug-drug Interaction Between Sitravatinib and a Cocktail of Substrates (NCT04887194)
- Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies (NCT04785287)
- Study of BND-22 in Participants With Advanced Solid Tumors (NCT04717375)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (NCT04387084)
- Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy (NCT04676633)
- JAB-3312 Activity in Adult Patients With Advanced Solid Tumors (NCT04720976)
- A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (NCT04772989)
- A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors (NCT04799054)
- A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy (NCT04847050)
- A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor (NCT04853017)
- A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors (NCT04859777)
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT04699188)
- A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors (NCT04761198)
- A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors (NCT04777994)
- M1231 in Participants With Solid Tumors (NCT04695847)
- SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer (NCT04742595)
- Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors (NCT04678921)
- Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-?� Inhibitor and PD-1 Inhibitor Cemiplimab (NCT04729725)
- Metastatic Solid Cancer Clinical Trial (NCT04739618)
- A Study of ALKS 4230 on the Tumor Microenvironment (NCT04592653)
- A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (NCT04606381)
- REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors (NCT04626635)
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (NCT04632992)
- A Study of PSB205 in Subjects With Advanced Solid Tumors (NCT03986606)
- Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (NCT04114136)
- Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers (NCT04295863)
- Study of AMG 256 in Adult Subjects With Advanced Solid Tumors (NCT04362748)
- A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors (NCT04440735)
- First-in-human Study of DRP-104 as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)
- Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies (NCT04552288)
- CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study (NCT04552704)
- COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (NCT04570839)
- Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (NCT04589845)
- GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402)
- 64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression (NCT04605614)
- Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma (NCT04609579)
- A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors (NCT04613492)
- Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (NCT04635995)
- FS120 First in Human Study in Patients With Advanced Malignancies (NCT04648202)
- LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors (NCT04666688)
- Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (NCT04669899)
- A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors (NCT04673942)
- A Phase 2 Trial for Patients With Metastatic Solid Cancer (NCT04713371)
- Phase Ib of L-NMMA and Pembrolizumab (NCT03236935)
- Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors (NCT03274661)
- Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases (NCT03457948)
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors (NCT02988960)
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667)
- A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (NCT03311334)
- M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability (NCT03436563)
- Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies (NCT03474640)
- Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (NCT03515551)
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (NCT03816332)
- A Study of ASP1951 in Subjects With Advanced Solid Tumors (NCT03799003)
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04219254)
- TAK-676 as Single Agent (SA) and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT04420884)
- PTX-35 in Patients With Advanced Solid Tumors (NCT04430348)
- A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126)
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (NCT04446351)
- First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors (NCT04457778)
- Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 (NCT04122625)
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (NCT04079712)
- Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab (NCT03973333)
- Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D) (NCT04098068)
- Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) (NCT04123366)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (NCT04317105)
- Tocilizumab for Patients With Cancer and COVID-19 Disease (NCT04370834)
- Study of ARRY-614 Plus Either Nivolumab or Ipilimumab (NCT04074967)
- RTX-240 Monotherapy (NCT04372706)
- Study of SRF388 in Patients With Advanced Solid Tumors (NCT04374877)
- A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (NCT04396821)
- A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors (NCT04408599)
- First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors (NCT04417465)
- Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies (NCT04418661)
- Avelumab and M6620 or Nedisertib for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912)
- KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors (NCT04237649)
- A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. (NCT04242147)
- Study of SRF617 in Patients With Advanced Solid Tumors (NCT04336098)
- Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (NCT04294576)
- Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab With and Without Chemotherapy in Locally Advanced or Metastatic Tumors (NCT02794571)
- Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors (NCT02827968)
- SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04291079)
- Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (NCT04319224)
- Study of DS-7300a in Participants With Advanced Solid Malignant Tumors (NCT04145622)
- Study to Assess AFM24 in Advanced Solid Cancers (NCT04259450)
- Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer (NCT02842125)
- Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors (NCT04007744)
- Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors (NCT04034238)
- Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors (NCT04262466)
- First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector (NCT04053283)
- Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT04096638)
- Precision Medicine for Patients With Identified Actionable Mutations (NCT04111107)
- A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors (NCT04116710)
- A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (NCT04134312)
- A Study in Subjects With Advanced Solid Tumors (NCT04156100)
- An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors (NCT04250155)
- IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors (NCT04261075)
- Safety and Efficacy Study of IMSA101 in Refractory Malignancies (NCT04020185)
- A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (NCT03953235)
- Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (NCT04095273)
- Study of CPI-200 in Patients With Advanced Tumors (NCT03953742)
- A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (NCT03954067)
- Study of GS-1423 in Participants With Advanced Solid Tumors (NCT03954704)
- An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (NCT03956680)
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111 (NCT03964233)
- An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (NCT03994601)
- A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor (NCT04042116)
- Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies (NCT04068194)
- Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors (NCT04084366)
- A Study in Subjects With Advanced Cancer (NCT04121676)
- Study of AMV564 in Subjects With Advanced Solid Tumors (NCT04128423)
- Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies (NCT04137900)
- Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects (NCT04167137)
- A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947)
- BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (NCT04021043)
- SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618)
- Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors (NCT03911557)
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers (NCT03935893)
- Anti-PD-1 +/- RT for MSI-H Solid Tumors (NCT04001101)
- AMG 510 Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (NCT04185883)
- Cabozantinib and Nivolumab for Carcinoid Tumors (NCT04197310)
- Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766)
- Safety Study of SEA-CD40 in Cancer Patients (NCT02376699)
- Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies (NCT03881488)
- TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers (NCT03884556)
- Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours (NCT03894540)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (NCT03907475)
- A Study of Bispecific Antibody MCLA-145 in Patients With Advanced Solid Tumors (NCT03922204)
- Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma (NCT03990571)
- PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (NCT03993379)
- Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors (NCT04157985)
- BDB001-102 Open Label Dose Escalation Combination w Atezolizumab (NCT04196530)
- rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors (NCT01071941)
- Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361)
- Study of BAY1834942 in Patients With Solid Tumors (NCT03596372)
- Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (NCT03607890)
- An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03661632)
- TCR-engineered T Cells in Solid Tumors (NCT03686124)
- A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) (NCT03861793)
- An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (NCT02754141)
- A Study of TRK-950 in Patients With Advanced Solid Tumors (NCT02990481)
- A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma (NCT03013218)
- CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors (NCT03113188)
- A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors (NCT03192345)
- A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors (NCT03238027)
- A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (NCT03495323)
- This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. (NCT03573544)
- Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors (NCT03588039)
- This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours) (NCT03604445)
- A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors (NCT03611868)
- IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (NCT03665129)
- Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors (NCT03684785)
- Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naive and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours. (NCT03697304)
- Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma (NCT03707093)
- A Study of MEDI5395 in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors (NCT03889275)
- Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 (NCT03721679)
- A Phase I Study of CS1001 in Advanced Solid Tumors (NCT03744403)
- Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (NCT03744468)
- MGD019 DART Protein in Unresectable/Metastatic Cancer (NCT03761017)
- A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas (NCT03763149)
- Study of INBRX-105 in Patients With Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (NCT03809624)
- TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas (NCT03815682)
- Nivolumab in Treating Patients With Autoimmune Disorders or Advanced, Metastatic, or Unresectable Cancer (NCT03816345)
- Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352)
- Copanlisib, Olaparib, and Durvalumab in Treating Patients With Metastatic or Unresectable Solid Tumors (NCT03842228)
- A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin (NCT04059588)
- A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects With Advanced Solid Tumors (NCT03260322)
- Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors (NCT04087018)
- Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers (NCT03512340)
- Oral AMXT 1501 Dicaprate in Combination With DFMO (NCT03536728)
- Durvalumab Long-Term Safety and Efficacy Study (NCT04078152)
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (NCT02489903)
- Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas (NCT03136055)
- Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NCT03240861)
- EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT03618381)
- TR1801-ADC in Patients With Tumors That Express c-Met (NCT03859752)
- Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (NCT04049617)
- Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease (NCT02843165)
- A Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) (NCT03148418)
- Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies (NCT03301896)
- MGD009/MGA012 Combination in Relapsed/Refractory Cancer (NCT03406949)
- Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (NCT03568058)
- A First-in-human Study of ILDR2 (Immunoglobulin-like Domain Containing Receptor 2) Function-blocking Antibody BAY1905254 (NCT03666273)
- Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer (NCT03711058)
- Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001) (NCT03833427)
- AO-176 in Multiple Solid Tumor Malignancies (NCT03834948)
- Study of TJ004309 in Combination With Atezolizumab (Tecentriq�) in Patients With Advanced or Metastatic Cancer (NCT03835949)
- AMG 404 in Patients With Advanced Solid Tumors. (NCT03853109)
- Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma (NCT03934814)
- A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors (NCT03946800)
- QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (NCT04050709)
- A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (NCT03448042)
- Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors (NCT03447314)
- Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) (NCT03249792)
- Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors (NCT03565991)
- A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors (NCT03637491)
- A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer (NCT03936959)
- A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation (NCT03684811)
- A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers (NCT03139370)
- Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations (NCT02607813)
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067)
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (NCT03313778)
- A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (NCT03590054)
- A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (NCT03668119)
- A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors (NCT02099058)
- Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors (NCT02281409)
- Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors (NCT02298959)
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458)
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02408861)
- A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers (NCT02452268)
- Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (NCT02501096)
- MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors (NCT02503774)
- MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors (NCT02517398)
- Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms (NCT02595866)
- Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02608268)
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors (NCT02608385)
- Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors (NCT02628574)
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread. (NCT02658890)
- A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors (NCT02671435)
- Study of the Safety and Efficacy of MIW815 (ADU-S100) in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (NCT02675439)
- AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers (NCT02694822)
- A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors (NCT02715284)
- A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies (NCT02740985)
- A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors (NCT02799095)
- A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (NCT02817633)
- A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors (NCT02819843)
- An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread (NCT02832167)
- KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (NCT02867007)
- Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors (NCT02903914)
- An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (NCT02913313)
- Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer (NCT02929862)
- A Study of LY3200882 in Participants With Solid Tumors (NCT02937272)
- A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours (NCT02952248)
- Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer (NCT02953782)
- Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) (NCT02964013)
- Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) (NCT02972034)
- Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers (NCT03005782)
- PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (NCT03013491)
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (NCT03030378)
- A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors (NCT03059823)
- An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (NCT03084471)
- A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors (NCT03099109)
- Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer (NCT03104699)
- First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03110107)
- This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment. (NCT03156114)
- A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread (NCT03166631)
- Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas (NCT03172936)
- Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001) (NCT03179436)
- Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278)
- Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor (NCT03239145)
- A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (NCT03251924)
- Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 or With TSR-042 and Bevacizumab (NCT03307785)
- Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03311412)
- A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (NCT03314935)
- Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma (NCT03322384)
- Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies (NCT03323398)
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (NCT03335540)
- An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (NCT03369223)
- Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (NCT03388632)
- An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers (NCT03400332)
- A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416335)
- CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors (NCT03425279)
- Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer (NCT03431948)
- FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy (NCT03440437)
- Phase I Study of RiMO-301 With Radiation in Advanced Tumors (NCT03444714)
- An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (NCT03444753)
- An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03446040)
- An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03459222)
- A Phase I Study of MSB2311 in Advanced Solid Tumors (NCT03463473)
- Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (NCT03486301)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (NCT03486873)
- Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03489343)
- Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas (NCT03489369)
- Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). (NCT03493945)
- Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma (NCT03502733)
- A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors (NCT03522142)
- INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors (NCT03589651)
- Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (NCT03651271)
- Phase 1a Study to Evaluate Immunogenicity of ASV (NCT03673020)
- Study of Avelumab-M3814 Combinations (NCT03724890)
- Study of CPI-100 in Patients With Advanced Tumors (NCT03781362)
- A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, With Cetuximab in Subjects With Advanced Solid Cancers (NCT03783403)
- SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies (NCT03831295)
- A Trial of AVID200, a Transforming Growth Factor-Beta Receptor (TGFBR) Inhibitor, in Patients Malignancies (NCT03834662)
- Phase 1 First Time in Humans (FTIH), Open Label Study of GSK3745417 Administered to Subjects With Advanced Solid Tumors (NCT03843359)
- First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (NCT03852511)
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272)
Targeted Therapy Trials (287)
- COAST Therapy in Advanced Solid Tumors and Prostate Cancer (NCT05036226)
- A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors (NCT05159700)
- A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors (NCT05240898)
- Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations (NCT05241873)
- A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations (NCT05242822)
- Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion (NCT05245500)
- A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors (NCT05268666)
- Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors (NCT05269316)
- RBS2418 Evaluation in Subjects With Unresectable or Metastatic Tumors (NCT05270213)
- Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors (NCT05275478)
- Phase I Study of TSN084 in Patients With Advanced Malignant Tumors (NCT05300438)
- OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) (NCT05340621)
- A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer (NCT04827810)
- Study of LaNova Medicines (LM-302) in Patients With Advance Solid Tumors (NCT05001516)
- Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation (NCT05023655)
- Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors (NCT05038839)
- Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (NCT05071209)
- AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors (NCT05094336)
- Strata PATH (Precision Indications for Approved Therapies) (NCT05097599)
- First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors (NCT05103046)
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Solid Tumors With Pathogenic Alterations in TSC1 or TSC2 Genes (PRECISION 1) (NCT05103358)
- First in Human Study of TORL-1-23 in Participants With Advanced Cancer (NCT05103683)
- A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948)
- A Study of ZN-c3 in Subjects With Malignant Tumors (NCT05128825)
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer (NCT05156866)
- First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer (NCT05159440)
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors (NCT05225584)
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors (NCT05228015)
- A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours (NCT04958226)
- A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors (NCT05071183)
- ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies (NCT05085548)
- A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1 (NCT05118789)
- A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation (NCT05119933)
- Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16 (NCT05178888)
- TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas (NCT01851369)
- Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors (NCT02211755)
- Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors (NCT02379416)
- Dabrafenib and/or Trametinib Rollover Study (NCT03340506)
- AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm (NCT03453489)
- Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials (NCT03477175)
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (NCT03947385)
- Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (NCT03975387)
- A Study of DT2216 in Relapsed/Refractory Malignancies (NCT04886622)
- A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours (NCT04914117)
- Milademetan in Advanced/Metastatic Solid Tumors (NCT05012397)
- A Study of NB004 in Patients With Advanced Solid Tumors (NCT05036291)
- KZR-261 in Subjects With Advanced Solid Malignancies (NCT05047536)
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors (NCT04826341)
- Study Of ATRN-119 In Patients With Advanced Solid Tumors (NCT04905914)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (NCT04972981)
- An Open-label Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a PARP Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05002868)
- Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (NCT04142437)
- JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation (NCT05002270)
- Open-Label Surufatinib in European Patients With NET (NCT04579679)
- Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer (NCT04965818)
- A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation (NCT04973163)
- A Phase I, Single Center, Open-label Clinical Pharmacology Study to Evaluate the Effect of Tipifarnib on Cardiac Safety in Subjects With Advanced Solid Malignancies (NCT04865159)
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors (NCT04774718)
- Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients (NCT05002140)
- A Study to Test Different Doses of BI 1810631 in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) (NCT04886804)
- A Study of BTX-A51 in People With Advanced Solid Tumor or Non-Hodgkin Lymphoma (NCT04872166)
- A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma (NCT04983810)
- A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations (NCT04762602)
- A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours (NCT02521844)
- A Phase I Open-label Study for Subjects With Advanced Malignancies (NCT04136834)
- Telotristat With Lutathera in Neuroendocrine Tumors (NCT04543955)
- Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor (NCT04810091)
- Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (NCT04802174)
- Study of RP-6306 in Advanced Solid Tumors (NCT04855656)
- First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) (NCT04882917)
- A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors (NCT04913285)
- DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors (NCT04985604)
- A Study of ERAS-007 in Patients With Advanced or Metastatic Solid Tumors (HERKULES-1) (NCT04866134)
- Study of MTB-9655, an Inhibitor of ACSS2, in Patients With Advanced Solid Tumors (NCT04990739)
- Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors (NCT04972110)
- Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors (NCT04750954)
- A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors. (NCT04892017)
- ARX517 in Subjects With Advanced Solid Tumor (NCT04662580)
- A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors (NCT04868877)
- A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma (NCT04970992)
- Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) (NCT04975256)
- Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors (NCT04879121)
- A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib (NCT04959266)
- A Study of NB003 in Patients With Advanced Malignancies (NCT04936178)
- Testing the Addition of an Anti-Cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Solid Tumors, Pancreatic Cancer, and Ovarian Cancer (NCT04616534)
- A Phase 1, Dose Escalation Study in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment (NCT04617522)
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl (NCT04713202)
- Study of ON 123300 in Patients With Advanced Cancer (NCT04739293)
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors (NCT04747470)
- First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors (NCT04761601)
- PF-07284892 in Participants With Advanced Solid Tumors (NCT04800822)
- To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment. (NCT04831944)
- To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment. (NCT04831996)
- Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations (NCT04665206)
- Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis (NCT04465760)
- TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations (NCT04770246)
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors (NCT04774952)
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068)
- A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies (NCT04678648)
- A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma (NCT04718675)
- Phase I Study of HL-085 in Patients With Advanced Solid Tumor Tumors (NCT04683354)
- First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors (NCT04622774)
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial (NCT04693468)
- A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (NCT04639219)
- A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors (NCT02428712)
- Futibatinib in Patients With Specific FGFR Aberrations (NCT04189445)
- Phase 1 Study of Oral TP-1454 (NCT04328740)
- Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy (NCT04393454)
- Cabozantinib in High Grade Neuroendocrine Neoplasms (NCT04412629)
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (NCT04419532)
- A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas (NCT04449562)
- A Study of PF-07265807 In Participants With Advanced or Metastatic Solid Tumors (NCT04458259)
- Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (NCT04488003)
- A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat (NCT04537715)
- A Study of ICP-192 in Patients With Advanced Solid Tumors (NCT04565275)
- This Study Will Evaluate PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (NCT04585750)
- A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors (NCT04587479)
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (NCT04648254)
- FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (NCT04670679)
- Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities (NCT04683250)
- Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors (NCT04686383)
- A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies (NCT03333031)
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (NCT03289741)
- Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors (NCT03335670)
- A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
- 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors (NCT03366116)
- Ribociclib (LEE011) Rollover Study for Continued Access (NCT02934568)
- Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer (NCT02451553)
- HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies (NCT03906643)
- Testing the Safety of CB-5339 in Patients With Cancer (NCT04372641)
- A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer (NCT04419623)
- A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors (NCT04443088)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (NCT04449874)
- A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer (NCT04474470)
- TAS-102 in Extrapulmonary Neuroendocrine Carcinoma (NCT04042714)
- Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (NCT04197713)
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (NCT04418167)
- Phase 1/2 Study of MRTX849 Plus TNO155 in Patients With Cancer Having a KRAS G12C Mutation (NCT04330664)
- Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (NCT03839940)
- PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (NCT04209595)
- RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors (NCT04252339)
- Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations (NCT04161391)
- ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer (NCT04267939)
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors (NCT03854227)
- A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis (NCT04089449)
- A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread (NCT04147247)
- KYN-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963)
- First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (NCT04006301)
- A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (NCT04083976)
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations (NCT04094610)
- A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation (NCT04165031)
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations (NCT04233567)
- Phase I Study of HL-085 in Patients With Advanced Solid Tumors (NCT03976050)
- A Study of CPI-0209 in Patients With Advanced Solid Tumors (NCT04104776)
- A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors (NCT04214093)
- A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies (NCT04241835)
- Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208) (NCT04003623)
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors (NCT03878095)
- Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca (NCT03919292)
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (NCT03950609)
- A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors (NCT03965845)
- A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies (NCT03886831)
- Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors (NCT03889795)
- A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers (NCT03907969)
- A Study of OKI-179 in Patients With Solid Tumors (NCT03931681)
- Study of FCN-437c in Patients With Advanced Solid Tumors (NCT03951116)
- A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (NCT04029688)
- M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (NCT04170153)
- Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials (NCT04184869)
- Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors (NCT03700294)
- An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors (NCT02278250)
- Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (NCT02503423)
- Study of ASTX029 in Subjects With Advanced Solid Tumors (NCT03520075)
- A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies (NCT03560882)
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation. (NCT03600883)
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors (NCT03634982)
- M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study (NCT03872427)
- A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm (NCT01905228)
- A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers (NCT02552953)
- Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors (NCT02723864)
- PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL (NCT03543813)
- First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas. (NCT03648372)
- First Time in Humans (FTIH) Study of GSK3368715 in Subjects With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL) (NCT03666988)
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of FN-1501 Monotherapy in Patients With Advanced Solid Tumors (NCT03690154)
- Phase I Study of TP-3654 in Patients With Advanced Solid Tumors (NCT03715504)
- Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors (NCT03895684)
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas (NCT03715933)
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer (NCT03726294)
- Hepatic Impairment Study for Lorlatinib in Cancer Patients (NCT03726333)
- Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014) (NCT03745989)
- TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors (NCT03756818)
- A Study of LY3405105 in Participants With Advanced Cancer (NCT03770494)
- SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors (NCT03784677)
- MRTX849 in Patients With Cancer Having a KRAS G12C Mutation (NCT03785249)
- A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors (NCT03797391)
- A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib (NCT03804515)
- A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers (NCT03843775)
- A Study of CFI-400945 Fumarate in Patients With Advanced Cancer (NCT01954316)
- A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency (NCT02873975)
- First-in-Human Study of KO-947 in Non-Hematological Malignancies (NCT03051035)
- WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification (NCT03253679)
- A Study of PLX2853 in Advanced Malignancies (NCT03297424)
- A Study of APX3330 in Patients With Advanced Solid Tumors (NCT03375086)
- A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (NCT04069026)
- Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03375320)
- A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands (NCT03234712)
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (NCT03864042)
- Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors (NCT03989115)
- Phase 1 Study of TPX-0022, a MET/CSF1R/SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET (NCT03993873)
- A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors (NCT03355066)
- A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03646071)
- A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies (NCT03926143)
- Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors (NCT02926768)
- This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (NCT03449381)
- Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (NCT02070549)
- First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965)
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316)
- ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations (NCT02761694)
- A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (NCT03093116)
- Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies (NCT03209401)
- Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair (NCT03318445)
- Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss (NCT03435250)
- EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (NCT01591356)
- A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors (NCT02549937)
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740)
- Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations (NCT01948297)
- A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors (NCT02608125)
- An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661)
- Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors (NCT03517956)
- Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (NCT03822117)
- Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) (NCT03834220)
- Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT. (NCT02272998)
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations (NCT03212274)
- A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (NCT02571036)
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270)
- Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies (NCT02648724)
- CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation (NCT03175224)
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (NCT03065062)
- A Study of ASN007 in Patients With Advanced Solid Tumors (NCT03415126)
- Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (NCT02639546)
- Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385)
- WEE1 Inhibitor AZD1775 in Treating Patients With SETD2-Deficient Locally Advanced or Metastatic Solid Tumors (NCT03284385)
- OLAParib COmbinations (NCT02576444)
- FdCyd and THU for Advanced Solid Tumors (NCT01534598)
- A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer (NCT01582191)
- Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus (NCT01822522)
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas (NCT01877382)
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02159989)
- Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer (NCT02219711)
- A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (NCT02301117)
- Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors (NCT02423057)
- Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02503709)
- Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (NCT02512926)
- Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy (NCT02516813)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (NCT02535312)
- A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. (NCT02579226)
- Study of INCB053914 in Subjects With Advanced Malignancies (NCT02587598)
- ATR Kinase Inhibitor VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931)
- A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma (NCT02609230)
- Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies (NCT02620839)
- A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors (NCT02667873)
- An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies (NCT02712905)
- An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) (NCT02997176)
- Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers (NCT03017833)
- Phase 2 Study of ONC201 in Neuroendocrine Tumors (NCT03034200)
- Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors (NCT03114319)
- M8891 First in Human in Solid Tumors (NCT03138538)
- Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors (NCT03154294)
- M3541 in Combination With Radiotherapy in Subjects With Solid Tumors (NCT03225105)
- Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors (NCT03237390)
- Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule (NCT03329001)
- Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850)
- APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies (NCT03386526)
- Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors (NCT03398720)
- First-in-human Study of Oral TP 0184 in Patients With Advanced Solid Tumors (NCT03429218)
- Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors (NCT03454035)
- Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors (NCT03510104)
- A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors (NCT03518554)
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors (NCT03526835)
- A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-64619178, an Inhibitor of Protein Arginine Methyltransferase 5 (PRMT5) in Participants With Advanced Cancers (NCT03573310)
- Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors (NCT03604783)
- Phase II Trial of AZD6738 Alone and in Combination With Olaparib (NCT03682289)
- Study of ABT-165 in Subjects With Advanced Solid Tumors (NCT01946074)
- Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors (NCT03348514)
- Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Solid Tumors (NCT03928314)
Other Trials (233)
- Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (NCT04745910)
- Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) (NCT05237934)
- Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumors (NCT05279690)
- Biomarkers For Immune Checkpoint Inhibitors (NCT04204434)
- Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s (NCT04488263)
- The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies (NCT04492735)
- AIMS Cancer Outcomes Study (NCT04495790)
- Study of RP-3500 in Advanced Solid Tumors (NCT04497116)
- Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (NCT05153772)
- Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients (NCT05164016)
- Psychophysical Studies of Cancer Therapy Pain (NCT00515060)
- Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer (NCT02108028)
- Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation (NCT02170181)
- Identifying Family Members in Need of Support While Caregiving and After Loss (NCT02455505)
- Metastatic Tumor Research and Outcomes Network (NCT02830451)
- Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy (NCT02960282)
- Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method? (NCT03261544)
- Cannabis Use in Cancer Patients (NCT03617692)
- Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients (NCT03757182)
- Variation in Cancer Centers' End-of-Life Quality (NCT03780816)
- Percutaneous Localization: Open-label Registry of Thoracic Surgery (NCT04066699)
- Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry (NCT04085029)
- Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers (NCT04090619)
- Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR) (NCT04095091)
- Patient Reported Symptom Control With THC or CBD Use (NCT04875286)
- Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients (NCT04939090)
- Low Dose ICG for Biliary Tract and Tumor Imaging (NCT04942665)
- Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values (NCT04942717)
- Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures (NCT04970212)
- Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein (NCT04976803)
- Cancer Pain Rehabilitation Program to Reduce Pain Related Distress, and Reliance of Pain Medication Through Multimodal Nonpharmacological Solutions (NCT05036408)
- Skeletal Metastasis Registry (NCT05058014)
- Development of a Digital Tool, MyInspiration, for the Improvement of Spiritual Well-Being in Patients With Cancer (NCT05198089)
- Collection of Outcomes Data for Pregnant Patients With Cancer (NCT00507572)
- Isolation and Culture of Immune Cells and Circulating Tumor Cells From Peripheral Blood and Leukapheresis Products (NCT00571389)
- Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors (NCT00900471)
- Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants (NCT00992303)
- Registry Study for Radiation Therapy Outcomes (NCT01255748)
- Validating Pain Scales in Children and Young Adults (NCT01639950)
- Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer (NCT02112188)
- The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study (NCT02520713)
- Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling (NCT02713334)
- Comprehensive Nutritional Geriatric Assessments in Identifying Malnutrition in Older Cancer Participants (NCT03035604)
- Biomarkers of Immune-Related Toxicity (NCT03409016)
- Solid Tumor Imaging MR-Linac (STIM Study) (NCT03500081)
- Prospective Tissue Collection Research Protocol (NCT03517917)
- Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors (NCT03739827)
- Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling (NCT03760952)
- Use of Google Translate to Enhance Patient Pain and Nausea Assessment and Satisfaction After General Anesthesia (NCT05060328)
- Assessment of Verbal Comprehension and Cognitive Processes in Patients Admitted to the Palliative and Supportive Care Unit (NCT05091632)
- Patient Perceptions of the Relational Empathy of Healthcare Practitioners From the Department of Emergency Medicine During the COVID-19 Pandemic (NCT05102656)
- Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies (NCT05108519)
- Role of Gut Microbiome in Cancer Therapy (NCT05112614)
- Identifying Outcome Measures for Assessing Nutritional Interventions Among Cancer Patients (NCT05118802)
- Cannabis Use Patterns Among Cancer Patients (NCT05132842)
- A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies (NCT05199272)
- ACP Intervention in the ED - A Pilot RCT (NCT05209880)
- A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R) (NCT01697930)
- Phase 1 Study of AlphaMedix in Adult Subjects With SSTR (+) NET (NCT03466216)
- The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors (NCT04551378)
- Major Complication Rate in Cancer Patients With Neutropenic Fever Potentially Eligible for a Hospital at Home Program (NCT04557709)
- Expanded Evaluation of the Survivorship Wellness Group Program in the Context of COVID-19 and Telehealth (NCT04630015)
- Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations (NCT04630431)
- Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine (NCT04751422)
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome (NCT04792463)
- Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants (NCT04939701)
- Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia (NCT04983901)
- Novel Optical Surface Image Guidance System for Beam-Gated Online Adaptive SBRT Delivery in Mobile Lower Lung and Upper Abdominal Malignancies (NCT05030454)
- Patient Considerations of Social Media Account Management After Death (NCT05035667)
- Impact of Aminoglycosides in Hypotensive Septic Oncology Patients (NCT05045963)
- Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer (NCT00804154)
- Stereotactic Body Radiation Therapy (SBRT) for Liver Mets (NCT01360606)
- Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome (NCT01494324)
- Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases (NCT02387905)
- Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases (NCT02480036)
- Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function (NCT02626312)
- Prospective Registry of Multiplex Testing (PROMPT) (NCT02665195)
- Financial Toxicity in Cancer Patients (NCT04592250)
- Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers (NCT04682847)
- Cios Mobile 3D Spin for Robotic Bronchoscopy (NCT04740047)
- Perception of Cure Among Patients With Metastatic Cancer (NCT04820894)
- Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues (NCT04822688)
- Efficacy and Safety of COVID-19 Vaccine in Cancer Patients (NCT04865133)
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors (NCT04871542)
- Culturally Tailored Nurse Coaching Study for Cancer Symptom Management (NCT04874584)
- Conversational Agents to Improve Quality of Life in Palliative Care (NCT02750865)
- Collaborative Care Intervention for Cancer Caregivers (NCT02944136)
- Oncotool for Cancer Medications (NCT03952312)
- Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer (NCT04042545)
- Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2) (NCT04283994)
- Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy (NCT04888988)
- Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses (NCT04960787)
- A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone (NCT05038124)
- Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy (NCT02710253)
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (NCT02724540)
- CapTem Plus Radioembolization for NET Liver Metastases (NCT04789109)
- A Study of Zanidatamab (ZW25) With ALX148 in Patients With Advanced HER2-expressing Cancer (NCT05027139)
- A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change (NCT05010031)
- Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 (NCT04795713)
- Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors (NCT03581357)
- Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors (NCT04552418)
- Care Transition Intervention for Patients With Cancer (NCT04640714)
- Study of Attention and Memory Treatments for Cancer Survivors (NCT04870320)
- Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers (NCT04870788)
- ALIGN Intervention in Patients With Advanced Cancer Discharging to a SNF (NCT04882111)
- Latinos' Beliefs and Communication About Advance Care Planning (NCT04889144)
- A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Technology for Treating Lower Extremity Lymphedema (NCT04897035)
- Technology-Enhanced Palliative Care for Advanced Cancer Patients (NCT04989556)
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) (NCT04939610)
- Dose-Escalated Spine SBRT for Localized Metastasis to the Spinal Column (NCT04802603)
- Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents (NCT04310345)
- ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies (NCT04412616)
- Yoga Intervention for the Improvement of Cancer-Related Stress in Cancer Survivors (NCT04754529)
- Virtual Reality Experiences for Anxiety and Pain Control (NCT04759183)
- Multi-Modal Palliative Care Intervention (NCT04773639)
- Expressive Writing for the Management of Stress in Cancer Survivors (NCT04776941)
- 5-aminolevulinic Acid In Advanced Malignancies (NCT04443686)
- Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors (NCT04721015)
- Coping Together: Couple-based Interventions for Cancer (NCT04590885)
- Imaging of Solid Tumors Using 68Ga-FAP-2286 (NCT04621435)
- Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases (NCT04218617)
- Radiation Therapy Alone Versus Radiation Therapy Plus Radiofrequency Ablation (RFA)/Vertebral Augmentation (NCT04375891)
- The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (NCT04572633)
- Feasibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (NCT04592887)
- Patient-caregiver Communication Intervention for Prognostic Understanding (NCT03833817)
- Effect of Opioid Infusion Rate for the Reduction of Breakthrough Cancer Pain in Patients With Cancer (NCT04296305)
- Lay Coach-Led Early Palliative Care for Underserved Advanced Cancer Caregivers: The Project ENABLE Cornerstone RCT (NCT04318886)
- Meaning-Centered Pain Coping Skills Training (NCT04431830)
- Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma (NCT04452292)
- Psychotherapy Intervention for Latinos With Advanced Cancer (NCT04537936)
- Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy (NCT04538625)
- Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy (NCT04560673)
- Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy (NCT04620369)
- Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer (NCT04697524)
- Feasibility of Aromatherapy in an Awake Craniotomy Environment (NCT03328143)
- An Upstream Palliative Care Intervention for Rural and African-American Advanced Cancer Family Caregivers (NCT03464188)
- Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) (NCT03273712)
- Radiosurgical Hypophysectomy for Bone Metasteses Pain (NCT03377517)
- UWCCC Molecular Tumor Board Registry (NCT03023202)
- Emergency Medicine Palliative Care Access (NCT03325985)
- Pain Management Support Study for Patients With Advanced Cancer (NCT03432247)
- Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors (NCT03507491)
- Avelumab Program Rollover Study (NCT03815643)
- A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer (NCT04492488)
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer (NCT00935090)
- Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis (NCT01705548)
- Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases (NCT01843413)
- 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients (NCT02334722)
- A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors (NCT03465618)
- DM-CHOC-PEN for Brain Tumors in AYA Subjects (NCT03668847)
- Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Participants With Advanced, Metastatic, or Recurrent Cancer (NCT03583255)
- The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer (NCT03668223)
- An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer (NCT03794635)
- Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy (NCT03525873)
- Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs (NCT03722511)
- A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (NCT02912949)
- Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors (NCT04234568)
- A Phase I Study to Evaluate the Safety and Clinical Activity of HH2853 (NCT04390737)
- Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies (NCT04475523)
- Post-Op Pain Control for Prophylactic Intramedullary Nailing (NCT03823534)
- Imaging Biomarkers of Lymphatic Dysfunction (NCT03760744)
- Ride to Care - Quality of Life With Transportation for RT (NCT03849742)
- Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits (NCT03856060)
- Phase I Study With 5-aminolevulinic Acid In Advanced Malignancies (NCT04381806)
- Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress (NCT04436835)
- Pilot Optimization Trial of Decision Partnering Intervention for Advanced Cancer Family Caregivers (NCT03947606)
- A Media Communication Intervention to Increase Engagement in Advance Care Planning Among Cancer Patients (NCT04208009)
- Quality Improvement Project for Advance Care Planning Tool in Hospital Medicine (NCT04296136)
- A Feasibility Study for the Use of Multispectral Optoacoustic Tomography in the Detection of Tumors (NCT04365413)
- Psychotherapy Intervention for Latinos With Advanced Cancer (NCT04015609)
- An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy (NCT04054154)
- Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer (NCT04068649)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (NCT03578081)
- UC Health Planning Study (NCT04012749)
- Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation (NCT01345539)
- Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone (NCT02880319)
- Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine (NCT03878485)
- Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice (NCT04049188)
- The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors (NCT04312282)
- Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases (NCT03093909)
- Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain (NCT03523351)
- Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (NCT04071756)
- Indocyanine Green (ICG) Guided Tumor Resection (NCT04084067)
- Exercise Therapy in Radiation Therapy (NCT03905356)
- Cordotomy in Reducing Pain in Patients With Advanced Cancer (NCT04119037)
- Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor (NCT04122118)
- Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801 (NCT04130516)
- Evaluate Eribulin ORA in Subjects With Solid Tumors (NCT04013217)
- Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors (NCT03875287)
- Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer (NCT03927885)
- Trial of DFP-14927 in Advanced Solid Tumors (NCT03943004)
- Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies (NCT03987685)
- Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol (NCT03997370)
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake (NCT03872778)
- A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies (NCT02730481)
- A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (NCT02797795)
- Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer (NCT03035409)
- Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma (NCT03168061)
- Systemic Therapy With or Without Local Consolidative Therapy in Treating Participants With Oligometastatic Solid Tumor (NCT03599765)
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors (NCT04047251)
- A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies (NCT02963168)
- Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors (NCT03051477)
- Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer (NCT03096340)
- Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients (NCT03137121)
- Integrative Medicine for Pain in Patients With Advanced Cancer Trial (IMPACT) (NCT04095234)
- Ipilimumab and Imatinib Mesylate in Advanced Cancer (NCT01738139)
- A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer (NCT02454010)
- Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1 (NCT02650986)
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) (NCT02702492)
- Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) (NCT02723955)
- Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A (NCT03950297)
- Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors (NCT01562626)
- A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies (NCT02250157)
- A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors (NCT02266745)
- A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors (NCT02389309)
- Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer (NCT02546531)
- A Phase I Study of PLX038 in Patients With Advanced Solid Tumors (NCT02646852)
- Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas (NCT02661542)
- Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (NCT02668770)
- Study of CGX1321 in Subjects With Advanced Solid Tumors (NCT02675946)
- Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001) (NCT02720068)
- First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors (NCT02729298)
- Ceramide NanoLiposome in Patients With Advanced Solid Tumors (NCT02834611)
- Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study (NCT02875548)
- Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy (NCT02925000)
- APG-115 in Patients With Advanced Solid Tumors or Lymphomas (NCT02935907)
- Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM) (NCT02765165)
- FID-007 in Treating Participants With Advanced Solid Tumors (NCT03537690)
- Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services (NCT03905720)
- A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile (NCT03416816)
- A Phase 1 Dose-escalation Study of FF 10832 for the Treatment of Advanced Solid Tumors (NCT03440450)
- A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors (NCT03762447)
- Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy (NCT03217669)
BreastCancerTrials.org © 2022 Quantum Leap Healthcare Collaborative.